Literature DB >> 19962918

The mammographic correlations with Basal-like phenotype of invasive breast cancer.

Xiao Wang1, Lan Chao, Liansheng Chen, Guohui Ma, Guangchao Jin, Mei Hua, Gengyin Zhou.   

Abstract

RATIONALE AND
OBJECTIVES: Mammography contributes to the improvement of breast carcinoma survival through early detection and treatment of breast lesions. The basal-like phenotype has been found to be an independent poor prognostic factor for breast cancer. The aim of this study was to determine the mammographic correlates of the basal-like phenotype of invasive breast cancer, and to more precisely predict patient outcome and those individuals who will be responsive to a specific therapeutic regimen.
MATERIALS AND METHODS: The mammographic findings in 267 patients with operable breast cancer were correlated with the basal-like subtype identified using immunohistochemical assessment of breast cancer cases, including estrogen receptor, progesterone receptor, HER-2/neu status, cytokeratin (CK5/6), and epidermal growth factor receptor.
RESULTS: Of the 267 invasive breast cancers, 40 (15%) were of the basal-like phenotype. Basal-phenotype tumors were significantly more likely to manifest as a mass (P = .002), most of which were indistinct margin (P =.035), at mammography, and architecture distortion at mammography (P = .002).
CONCLUSION: The mammographic appearances of basal-like tumors, more mass and architecture distortion, suggest more rapid carcinogenesis. Additional studies are warranted to further refine prognosis, and to optimize treatment in patients with basal-like breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962918     DOI: 10.1016/j.acra.2009.10.011

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  3 in total

1.  Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors.

Authors:  Yu-Mee Sohn; Kyunghwa Han; Mirinae Seo
Journal:  Iran J Radiol       Date:  2016-07-04       Impact factor: 0.212

2.  Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2013-06-19       Impact factor: 5.344

3.  Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.

Authors:  Sen Jiang; You-Jia Hong; Fan Zhang; Yang-Kang Li
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.